ZATELLI, Maria Chiara
 Distribuzione geografica
Continente #
NA - Nord America 15.651
EU - Europa 4.533
AS - Asia 2.275
SA - Sud America 13
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 5
AF - Africa 1
Totale 22.488
Nazione #
US - Stati Uniti d'America 15.632
CN - Cina 1.610
DE - Germania 1.275
UA - Ucraina 1.085
IT - Italia 704
TR - Turchia 611
GB - Regno Unito 454
FI - Finlandia 261
SE - Svezia 260
PL - Polonia 202
RU - Federazione Russa 155
FR - Francia 53
BE - Belgio 37
VN - Vietnam 16
CA - Canada 13
EU - Europa 10
IN - India 9
NL - Olanda 9
IR - Iran 8
HK - Hong Kong 7
IE - Irlanda 7
BR - Brasile 5
MX - Messico 5
DK - Danimarca 4
ES - Italia 4
RO - Romania 4
AU - Australia 3
CH - Svizzera 3
EC - Ecuador 3
JP - Giappone 3
KR - Corea 3
SG - Singapore 3
BG - Bulgaria 2
CZ - Repubblica Ceca 2
GR - Grecia 2
HU - Ungheria 2
LV - Lettonia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PE - Perù 2
PT - Portogallo 2
AR - Argentina 1
BD - Bangladesh 1
CL - Cile 1
KZ - Kazakistan 1
MD - Moldavia 1
MK - Macedonia 1
NP - Nepal 1
PA - Panama 1
PK - Pakistan 1
TW - Taiwan 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 22.488
Città #
Woodbridge 2.085
Fairfield 1.882
Chandler 1.487
Ashburn 1.378
Jacksonville 1.264
Houston 1.195
Ann Arbor 842
Seattle 736
Wilmington 706
Cambridge 626
Izmir 409
Nanjing 373
Beijing 328
Princeton 311
Addison 276
Ferrara 230
Warsaw 202
San Diego 182
Boardman 169
Milan 153
Shanghai 133
Shenyang 119
New York 117
Nanchang 110
Dearborn 100
Bremen 92
Hebei 85
Changsha 65
Tianjin 59
Mountain View 56
Jiaxing 55
Falls Church 52
Washington 50
Jinan 48
Kunming 41
Redwood City 38
London 37
Norwalk 35
Brussels 31
Tappahannock 29
Guangzhou 27
Helsinki 27
Orange 26
Ningbo 25
San Mateo 23
Auburn Hills 22
Bologna 20
Des Moines 19
Indiana 19
Leawood 17
Dong Ket 16
Hangzhou 16
Hefei 16
Taizhou 16
Zhengzhou 15
Lanzhou 11
Redmond 11
Augusta 10
Chicago 10
Los Angeles 10
Changchun 9
Rome 8
Ferrara di Monte Baldo 7
Haikou 7
Monmouth Junction 7
Padova 7
Ardabil 6
Hong Kong 6
Walnut 6
Yellow Springs 6
Chengdu 5
Dallas 5
Kilburn 5
Mumbai 5
Munich 5
Philadelphia 5
Prescot 5
Toronto 5
Chiswick 4
Fuzhou 4
San Francisco 4
Siena 4
Southwark 4
Treviso 4
Verona 4
Waanrode 4
Andover 3
Castelnuovo Rangone 3
Cordovado 3
Dublin 3
Jinhua 3
Lappeenranta 3
Mestre 3
Montréal 3
Napoli 3
Paris 3
Poggio Renatico 3
Reggio Emilia 3
Taiyuan 3
Terni 3
Totale 16.725
Nome #
SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma 334
Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds 233
Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas 156
Magmas Overexpression Inhibits Staurosporine Induced Apoptosis in Rat Pituitary Adenoma Cell Lines 155
Igf-I influences everolimus activity in medullary thyroid carcinoma 155
Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses 148
Recettori della somatostatina e carcinoma midollare della tiroide: prospettive future. 148
Role of Ultrasonographic/Clinical Profile, Cytology, and BRAF V600E Mutation Evaluation in Thyroid Nodule Screening for Malignancy: A Prospective Study 147
Applicability of laparoscopic approach to the resection of large adrenal tumours: a retrospective cohort study on 200 patients 144
Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism 141
Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. 136
Increase in Peripheral CD3-CD56brightCD16- Natural Killer Cells in Hashimoto's Thyroiditis Associated with HHV-6 Infection 136
A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization 135
Relevance of BRAF(V600E) Mutation Testing Versus RAS Point Mutations and RET/PTC Rearrangements Evaluation in the Diagnosis of Thyroid Cancer 133
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion. 132
Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. 131
Inhibition of epithelial growth factor receptor can play an important role in reducing cell growth and survival in adrenocortical tumors 128
Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids 128
Cyclin D1 levels are involved in the resistance to m-TOR inhibitors in human bronchial carcinoids 127
Are Evidence-Based Guidelines Reflected in Clinical Practice? An Analysis of Prospectively Collected Data of the Italian Thyroid Cancer Observatory 127
Levels of p27 sensitize to dual PI3K/mTOR inhibition 126
Predictors of Pituitary Dysfunction in Patients Surviving Ischemic Stroke 126
X-linked acrogigantism syndrome: clinical profile and therapeutic responses 124
Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells 123
Involvement of PKCβ and PKCδ isoforms in TSH signaling pathway in thyroid cancer cell lines 121
mTOR, AKT, p70S6K and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids 120
Cerebral aneurysm and acromegaly: a case report 119
Pituitary side effects of old and new drugs. 119
The cytotoxic effect of sunitinib on human bronchial carcinoid cell lines and primary cultures is counteracted by EGF and IGF-1 but not by VEGF 118
Unexpected activation of pituitary-adrenal axis in healthy young and elderly subjects during somatostatin infusion 117
Early onset acromegaly associated with a novel deletion in CDKN1B 5'UTR region 115
null 114
Proteasomes and RARS modulate AIMP1/EMAP II secretion in human cancer cell lines. 114
In vitro testing of new somatostatin analogs on pituitary tumor cells 114
VEGF autocrine secretion is enhanced by EGFR activation trough ERK1/2 phosphorylation in human adrenocortical carcinoma cell lines 114
Rare diseases in clinical endocrinology: a taxonomic classification system. 114
null 113
Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation 113
The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells. 113
Epidermal growth factor pathway as a possible target in the medical therapy of bronchial carcinoids 113
IGF-I Proliferative Effects Are Inhibited by Targeting PKC in Human Endocrine Tumor Cells 112
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression. 112
Functional characterization of a new deletion in CDKN1B 5'-UTR region 112
Radio-guided selective compartment neck dissection improves staging in papillary thyroid carcinoma: a prospective study on 345 patients with a 3-year follow-up. 112
RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease 112
Magmas, a Gene Newly Identified as Overexpressed in Human and Mouse ACTH-Secreting Pituitary Adenomas, Protects Pituitary Cells from Apoptotic Stimuli 111
null 111
HHV-6A in vitro infection of thyrocytes and T cells alters the expression of miRNA associated to autoimmune thyroiditis 111
BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine needle aspiration biopsies. 111
Runx2 mRNA Expression in the Tissue, Serum, and Circulating Non-Hematopoietic Cells of Patients with Thyroid Cancer 110
Should aip gene screening be recommended in family members of FIPA patients with R16H variant? 110
Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. 110
Acromegaly secondary to an incidentally discovered growth-hormone-releasing hormone secreting bronchial carcinoid tumour associated to a pituitary incidentaloma 109
Somatostatin receptor subtype 1 selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. 109
mTOR mediated IGF1 proliferative effects on a rat pituitary GH/PRL secreting pituitary adenoma cell line 109
Magmas, a Novel Over-Expressed Gene in Pituitary Rat Cell Lines and in Human Pituitary Adenomas: A New Pituitary Biomarker? 108
mTOR, p70S6K, AKT and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids 107
null 106
Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. 105
Virologic and immunologic evidence supporting an association between HHV-6 and Hashimoto’s thyroiditis 105
Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH) 105
Therapeutic concentrations of mitotane (o,p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. 104
miR-15a and miR-16-1 down-regulation in pituitary adenomas 104
Growth hormone excess promotes breast cancer chemoresistance 103
Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame 103
Recettori della Somatostatina e Carcinoma Midollare della Tiroide: prospettive future. 102
Growth Hormone Enhances Breast Cancer Chemoresistance by Inhibiting JNK-Mediated Apoptosis 102
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression 102
Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells 102
null 101
Magmas, a novel over-expressed gene in Pituitary rat cell lines and in human pituitary adenomas: a new pituitary bio marker? 101
Utilization of luminescent technology to develop a kinase assay: Cdk4 as a model system 101
Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. 101
MicroRNAs and possible role in pituitary adenoma 100
Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT. 100
Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects 100
MTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors 100
N-carbamidoyl-4-((3-ethyl-2,4,4-trimethylcyclohexyl)methyl)benzamide enhances staurosporine cytotoxic effects likely inhibiting the protective action of Magmas toward cell apoptosis 100
Evaluation of bone markers and structure in subclinical Cushing’s syndrome 99
Inhibitory effect of dihydrotestosterone on human thyroid cell growth 99
Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines 99
EGF and IGF1 affect sunitinib activity in BP-NEN: New putative targets beyond VEGFR? 99
An in vivo OctreoScan-negative adrenal pheochromocytoma expresses somatostatin receptors and responds to somatostatin analogs treatment in vitro 98
null 98
Evidence for androgen receptor gene expression and growth inhibitory effect of dihydrotestosterone on human adrenocortical cells 98
Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT 97
BRAFV600E analysis on fine needle aspiration biopsy increases diagnostic accuracy for papillary thyroid cancer in clinically unsuspected nodules 97
Effects of two mTOR inhibitors on in-vitro models of GH-secreting pituitary adenomas 97
Expression of functional KISS1 and KISS1R system is altered in human pituitary adenomas: evidence for apoptotic action of kisspeptin-10. 97
Response to Pitoia and Niepomniszcze Thyroid 97
Somatostatin receptors: from basic science to clinical approach - Thyroid. 96
Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review 96
Cushing in a Leaf: Endocrine Disruption From a Natural Remedy 95
Deletion of exons 1-3 of the MEN1 gene in a large Italian family causes the loss of menin expression 93
null 92
Real-time elastography in autonomously functioning thyroid nodules: relationship with TSH levels, scintigraphy, and ultrasound patterns 92
Acute administration of human galanin in normal subjects reduces the potentiating effect of pyridostigmine-induced cholinergic enhancement on release of norepinephrine and pancreatic polypeptide 91
Somatostatin and thyroid 91
Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing 91
Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients 91
Totale 11.550
Categoria #
all - tutte 87.017
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.962
Totale 90.979


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.182 0 0 0 0 0 0 0 0 0 500 569 1.113
2019/20204.820 796 148 148 704 317 614 421 481 358 498 255 80
2020/20213.348 271 234 199 449 206 341 101 368 98 477 429 175
2021/20222.754 113 256 179 54 118 160 129 151 114 223 266 991
2022/20233.186 321 277 130 435 467 440 168 266 385 26 165 106
2023/20241.549 151 193 103 57 138 315 56 454 58 24 0 0
Totale 22.954